Sangamo Announces ASGCT 2024

Translating groundbreaking science into tomorrow’s cures

Explore our science

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Explore our latest corporate presentation by clicking below to stay informed and gain valuable insights into our company’s vision, achievements, and roadmap.

View the corporate presentation

The Latest at Sangamo


Company pipeline and business development opportunities

Clinical Trials

Indication Preclinical Phase 1/2 Pivotal Partner Anticipated Milestones*
Chronic Neuropathic Pain (Nav 1.7) Data presented at ASGCT 2023 Q4 24: Nav 1.7 IND submission
Prion Disease Data presented at Prion 2023 Q4 25: Prion CTA submission
Tauopathies As early as Q4 25: Tau IND submission
ALS/FTD alexion logo
Huntington's Disease takeda logo
Indication Preclinical Phase 1/2 Pivotal Partner Anticipated Milestones*
Hemophilia A (Giroctogene fitelparvovec) Data presented at ASH 2023 pfizer logo Mid-2024: Phase 3 AFFINE trial pivotal readout
Early 2025: BLA and MAA submissions
Fabry Disease (Isaralgagene civaparvovec) Data presented at WORLDSymposium 2024 IH24: Phase 1/2 STAAR study dosing completion
Renal Transplant (TX200) Six patients dosed in Phase 1/2 IH24: Phase 1/2 STEADFAST study dosing completion